EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment Strategies for Metastatic Castration‐Sensitive Prostate Cancer: Current Evidence and Future Directions

Kiyoshi Takahara iD, Akihito Takeuchi, Masanobu Saruta, Atsuhiko Yoshizawa, Takuhisa Nukaya iD, Masashi Takenaka, Manabu Ichino, Hitomi Sasaki

International Journal of Urology · 2026

DOI: 10.1111/iju.70375 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2026. Verfasst von Kiyoshi Takahara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic castration‐sensitive prostate cancer (mCSPC) is a biologically heterogeneous disease with a variable clinical course. Over the past decade, the treatment landscape for mCSPC has evolved significantly, shifting from androgen deprivation therapy (ADT) alone to combination approaches, including chemotherapy and novel androgen receptor pathway inhibitors. Landmark trials, such as CHAARTED, STAMPEDE, and LATITUDE, have demonstrated significant survival benefits with the addition of docetaxel or abiraterone to ADT, leading to changes in clinical guidelines and practice. More recently, triplet therapies combining ADT, docetaxel, and androgen receptor signaling inhibitors have shown further improvement in patient outcomes, although optimal patient selection remains unclear. Furthermore, advances in molecular profiling and imaging have enabled more precise stratification of patients, allowing for personalized treatment strategies. This review provides a comprehensive overview of the current evidence regarding treatment strategies for mCSPC, including key clinical trials, real‐world data, and ongoing research. Additionally, we discuss emerging therapies and potential future directions, such as the integration of novel agents targeting DNA repair pathways or radiopharmaceuticals targeting prostate‐specific membrane antigen. As the therapeutic landscape continues to expand, a more nuanced understanding of disease biology and patient characteristics is essential for guiding individualized care and improving long‐term outcomes in men with mCSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsProstatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAndrogen Receptor AntagonistsDocetaxelPrecision Medicine

Stichwörter der Autor:innen

ARSImCSPCtriplet therapy

Substanzen

Androgen AntagonistsAndrogen Receptor AntagonistsDocetaxel

Autor:innen und Institutionen

  • Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan.

ORCID-Profile: Kiyoshi Takahara, Takuhisa Nukaya

Zitieren

APA

Takahara, K., Takeuchi, A., Saruta, M., Yoshizawa, A., Nukaya, T., Takenaka, M., Ichino, M., & Sasaki, H. (2026). Treatment Strategies for Metastatic Castration‐Sensitive Prostate Cancer: Current Evidence and Future Directions. International Journal of Urology. https://doi.org/10.1111/iju.70375

Vancouver

Takahara K, Takeuchi A, Saruta M, Yoshizawa A, Nukaya T, Takenaka M, et al. Treatment Strategies for Metastatic Castration‐Sensitive Prostate Cancer: Current Evidence and Future Directions. International Journal of Urology. 2026. doi:10.1111/iju.70375

BibTeX
@article{Takahara2026,
  author = {Takahara, Kiyoshi and Takeuchi, Akihito and Saruta, Masanobu and Yoshizawa, Atsuhiko and Nukaya, Takuhisa and Takenaka, Masashi and Ichino, Manabu and Sasaki, Hitomi},
  title = {Treatment Strategies for Metastatic Castration‐Sensitive Prostate Cancer: Current Evidence and Future Directions},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70375}
}
Kostenlos starten →